60 -5 (91) 2026 - Tilavov M.T., Sanayeva M.J. - COMPARATIVE EVALUATION OF THE ESRS, SAS, AND AIMS SCALES IN THE DIAGNOSIS OF EXTRAPYRAMIDAL DISORDERS IN PSYCHIATRIC PATIENTS

COMPARATIVE EVALUATION OF THE ESRS, SAS, AND AIMS SCALES IN THE DIAGNOSIS OF EXTRAPYRAMIDAL DISORDERS IN PSYCHIATRIC PATIENTS

Tilavov M.T. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Sanayeva M.J. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Extrapyramidal symptoms (EPS) induced by antipsychotic therapy remain a major clinical problem in modern psychiatry. Motor adverse effects significantly affect treatment tolerability, disease course, and functional outcomes. Standardized rating scales such as the Extrapyramidal Symptom Rating Scale (ESRS), Simpson–Angus Scale (SAS), and Abnormal Involuntary Movement Scale (AIMS) are widely used for EPS assessment. The aim of this review is to compare these scales in terms of diagnostic accuracy, clinimetric properties, and clinical applicability based on recent publications. The analysis demonstrates that ESRS provides comprehensive assessment of different EPS phenotypes, SAS is optimal for routine evaluation of drug-induced parkinsonism, while AIMS remains the gold standard for tardive dyskinesia monitoring. Appropriate scale selection improves diagnostic accuracy and antipsychotic treatment optimization.

Keywords: extrapyramidal symptoms; antipsychotics; ESRS; SAS; AIMS; diagnosis.

First page

348

Last page

351

For citation:Tilavov M.T., Sanayeva M.J. - COMPARATIVE EVALUATION OF THE ESRS, SAS, AND AIMS SCALES IN THE DIAGNOSIS OF EXTRAPYRAMIDAL DISORDERS IN PSYCHIATRIC PATIENTS//New Day in Medicine 5(91)2026 348-351 https://newdayworldmedicine.com/en/new_day_medicine/5-91-2026

List of References

1. Ali T, Sisay M, Tariku M, Mekuria AN, Desalew A. Antipsychotic-induced extrapyramidal side effects: a systematic review and meta-analysis of observational studies. PLoS One. 2021;16(9):e0257129. doi:10.1371/journal.pone.0257129.
2. Gebremariam EH, et al. Prevalence and associated factors of antipsychotic-induced extrapyramidal symptoms. BMC Psychiatry. 2025.
3. Martino D, Karnik V, Bhidayasiri R, Hall DA, Hauser RA, Macerollo A, et al. Scales for antipsychotic-associated movement disorders: systematic review, critique, and recommendations. Mov Disord. 2023;38(6):1008-1026. doi:10.1002/mds.29392.
4. Chouinard G, Chouinard VA, Alphs L. The ESRS and its abbreviated version. Psychother Psychosom. 2023.
5. Hauser RA, et al. Minimal clinically important change in AIMS. Parkinsonism Relat Disord. 2022.
6. Trosch RM, et al. Validation of the Clinician’s Tardive Inventory. J Clin Psychopharmacol. 2025.
7. El-Mallakh RS, et al. Telehealth for assessing tardive dyskinesia. Telemed E Health. 2023.
8. Bhidayasiri R, et al. Tardive dyskinesia in Asia. Front Neurol. 2024.
9. Caroff SN. Diagnosis and treatment of tardive dyskinesia. CNS Spectr. 2023.
10. Rekhi G, et al. Impact of extrapyramidal symptoms on quality of life. J Psychopharmacol. 2022.

    file

    download